The leading causes were angiotensin-converting enzyme inhibitors (ACEI) and HMG-CoA reductase inhibitors (statins), which are commonly prescribed for hypertension and dyslipidemia patients. This evidence concerns the gene HMGCR and metabolic syndrome.